ALBUQUERQUE, N.M., Oct. 25 /PRNewswire-FirstCall/ -- Biomoda, Inc. (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today an agreement with Clinical Research Center of Cape Cod (CRCCC) of West Yarmouth, Mass. to provide lung sputum samples for Biomoda’s internal clinical programs.
Under a collection protocol approved by an Institutional Review Board, CRCCC (http://www.crccc.com) will collect and provide samples necessary for Biomoda’s commercialization program of its non-invasive sputum assay for the early detection of lung cancer. CRCCC is a leading medical research firm with products and services that support the pharmaceutical, biotechnology, diagnostic and genomics industries.
“CRCCC will deliver quality, state-of-the-art services to help us bring our products to the market,” said John Cousins, President of Biomoda. “We are aggressively pursuing internal studies that, coupled with our clinical work with other organizations, will make our assay available to the public in the short term. CRCCC will help make that happen by supplying quality samples in a timely manner.”
Biomoda’s early lung cancer detection technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.
Contact: John Cousins (505) 821-0875
CONTACT: John Cousins, +1-505-821-0875, for Biomoda, Inc.
Web site: http://www.biomoda.com/
http://www.crccc.com/
